TPG is said to be working with advisers while monitoring a separate healthcare IPO in Malaysia as it evaluates exit options. Discussions remain preliminary and the firm could also choose to retain its stake. The potential transaction highlights continued private equity interest in Southeast Asia's healthcare sector, where rising incomes and expanding middle classes are driving long-term demand for medical services. Subscribe to our Newsletter to increase your edge. Don't worry about the news anymore, through our newsletter you'll receive weekly access to what is happening. Join 120,000 other PE professionals today....
The transaction underscores private credit's growing role in healthcare buy-and-build strategies. Moreover, it highlights how direct lenders are increasingly partnering with private equity sponsors to structure large-scale growth financings. Subscribe to our Newsletter to increase your edge. Don't worry about the news anymore, through our newsletter you'll receive weekly access to what is happening. Join 120,000 other PE professionals today....
The vehicle, which was significantly oversubscribed, was led by Hayfin Capital Management and supported by institutional investors including BNP Paribas AM and Altamar CAM. The structure provides liquidity to existing limited partners at three times invested capital, while allowing Alantra to retain exposure to a high-conviction asset. The transaction also introduces Merieux Equity Partners as a 20% minority shareholder through its buyout fund, Merieux Participations 4. The addition of a specialist healthcare investor signals a deliberate shift from build-and-integrate to scale-and-expand, as Health in Code prepares to accelerate its international footprint. Founded in 2020 through the combination of Health in Code, Imegen, Genycell Biotech, and later Genologica, the business has developed an integrated clinical genomics platform serving hospitals and healthcare professionals in more than 30 countries. The company combines next-generation sequencing services, diagnostic kits, and its proprietary DataGenomics bioinformatics platform, with a focus on cardiology, oncology, neurology, and rare diseases ....
Arcadia has built a portfolio of over-the-counter medicines and wellness brands, including Nizoral, Colace, Senokot, CloSYS, Betadine, and Kaopectate. During Mubadala's investment period, the company's revenue tripled and profitability improved materially. 'It has been a privilege to partner with Bansk, Mike DeBiasi and the Arcadia team over the past four years,' Philip Yifei Bao, director of private equity at Mubadala, said in a statement. 'We are incredibly proud to have supported the transformation of Arcadia into the leading North American consumer health and wellness platform.' Subscribe to our Newsletter to increase your edge. Don't worry about the news anymore, through our newsletter you'll receive weekly access to what is happening. Join 120,000 other PE professionals today....
